Agile Therapeutics (NASDAQ:AGRX) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research note published on Friday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group reissued a hold rating on shares of Agile Therapeutics in a research note on Monday, March 18th.

Agile Therapeutics Stock Performance

AGRX opened at $0.37 on Friday. The stock has a market cap of $2.54 million, a price-to-earnings ratio of -0.04 and a beta of 1.42. The stock’s 50 day moving average price is $0.72 and its 200-day moving average price is $1.49. Agile Therapeutics has a one year low of $0.20 and a one year high of $7.50.

Institutional Trading of Agile Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp purchased a new position in Agile Therapeutics in the 2nd quarter worth $32,000. Vanguard Group Inc. purchased a new position in Agile Therapeutics in the 4th quarter worth $40,000. Jane Street Group LLC purchased a new position in Agile Therapeutics in the 2nd quarter worth $108,000. Armistice Capital LLC raised its stake in Agile Therapeutics by 10.2% in the 4th quarter. Armistice Capital LLC now owns 108,000 shares of the specialty pharmaceutical company’s stock worth $211,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in Agile Therapeutics in the 4th quarter worth $32,000. Hedge funds and other institutional investors own 10.92% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.